The application of Ipilimumab in treatment of patients with metastatic melanoma
- Authors: Samoilenko I.V1, Harkevitch G.Y.1, Demidov L.V1
-
Affiliations:
- The N.N. Blokhin Russian oncologic national center
- Issue: Vol 21, No 1 (2015)
- Pages: 4-9
- Section: Articles
- URL: https://bakhtiniada.ru/0869-2106/article/view/38227
- DOI: https://doi.org/10.17816/rmj38227
- ID: 38227
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
I. V Samoilenko
The N.N. Blokhin Russian oncologic national centerхирургическое отделение № 10 115478 Moscow, Russia
Galina Yu. Harkevitch
The N.N. Blokhin Russian oncologic national center
Email: gkharkevich@mail.ru
MD, PhD, Leading Researcher Dept. of Biotherapy 115478 Moscow, Russia
L. V Demidov
The N.N. Blokhin Russian oncologic national centerхирургическое отделение № 10 115478 Moscow, Russia
References
- Burnet M. Cancer: a biological approach. I. The processes of control. Br. Med. J. 1957; 1(5022): 779-86.
- Dunn G.P. et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002; 3(11): 991-8.
- Vesely M.D., Schreiber R.D. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann. N. Y. Acad. Sci. 2013; 1284: 1-5.
- Hodi F.S. et al., Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010; 363(8): 711-23.
- Ribas A., Butterfield L.H., Economou J.S. Genetic immunotherapy for cancer. Oncologist. 2000; 5(2): 87-98.
- Ott P.A., Hodi F.S., Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin. Cancer Res. 2013; 19(19): 5300-9.
- Assi H., Wilson K.S. Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases. Curr. Oncol. 2013; 20(2): e165-9.
- Delyon J. et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann. Oncol. 2013; 24(6): 1697-703.
- Maio M. Survival amalysis with 5 years of follow up in phase III study of ipilimumab and dacarbazine in metastatic melanoma: ESMO oral presentation 3704. Eur. J. Cancer. 2013.
- Wolchok J.D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 2009; 15(23): 7412-20.
- Weber J.S. et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013; 119(9): 1675-82.
Supplementary files
